Abstract 1485P
Background
Pembrolizumab is the standard first-line treatment for patients with metastatic Non-Small Cell Lung Cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression of ≥50%. However, early loss of clinical benefit is observed in many cases. There is a need to identify predictors of this phenomenon in the real-world population.
Methods
This study is a retrospective analysis of patients (pts) with stage IV NSCLC treated with pembrolizumab in routine practice, who received treatment for at least 6 weeks. Inclusion criteria included good performance status (ECOG 0-1), no active brain metastases, and no EGFR or ALK alterations. The median progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The log-rank test and Cox regression model were used for uni- and multivariate analysis.
Results
A group of 216 pts were included. The objective response rate was 35.6%, 25.5% of pts had PD, while 11.2% of pts died before the first CT-scan. Median PFS and OS were 9.88 months (95% CI 4.85-14.92; 127 events) and 14.88 months (95% CI 9.84-19.91; 122 events), respectively. The median Systemic Inflammatory Index (SII) was 1260 in the overall population. In univariate analysis, SII >1260 had a negative impact on PFS (p=0.047) and OS (p<0.022). Tumour burden ≥111.5 mm (p<0.045) was a negative prognostic factor for OS. Other factors assessed were not relevant. An increase in the SII of more than 25% after 6 weeks of treatment correlated with a higher likelihood of early progression (p<0.001) and shorter OS (p<0.001). The differences were more pronounced in the subgroup of patients with an initial SII >1260. On multivariate analysis, higher tumour burden (HR 1.52, p=0.028, 95%CI 1.043-2.018) and an increase in SII at 6 weeks of more than 25% (HR 2.62, p<0.001;95%CI 1.625-4.234) were found to be negative prognostic factors for OS.
Conclusions
Pembrolizumab is effective in pts treated in daily practice. Taking into account additional factors, such as inflammatory index, may help to identify the optimal patient population. The dynamics of SII after 6 weeks of treatment may be a surrogate for clinical benefit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Knetki-Wroblewska: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Roche, MSD, Takeda, Amgen, AstraZeneca, Boehringer Ingelheim, Ipsen; Financial Interests, Personal, Advisory Board: Takeda, Boehringer Ingelheim, Bristol Myers Squibb. A. Piórek: Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca, Takeda. S. Tabor: Financial Interests, Personal, Invited Speaker: MSD, BMS; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Other, Travel grant: AstraZeneca. K. Winiarczyk: Financial Interests, Personal, Invited Speaker: BMS, Pfizer. P. Sobczuk: Financial Interests, Personal, Other, Travel grant: Novartis; Financial Interests, Personal, Other, Travel Grant: MSD, BMS; Financial Interests, Personal, Invited Speaker: Swixx BioPharma, BMS, Gilead; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Stocks/Shares: CelonPharma; Non-Financial Interests, Institutional, Product Samples: Immutep; Non-Financial Interests, Leadership Role, Board Member, Chair of Young Oncologists Section: Polish Society of Clinical Oncology. A. Pluzanski: Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca, Roche, Pfizer; Financial Interests, Personal, Advisory Board: MSD, BMS. D.M. Kowalski: Financial Interests, Personal, Advisory Board: MSD, BMS; Financial Interests, Personal, Invited Speaker: MSD, BMS, AstraZeneca, Roche, Pfizer; Financial Interests, Personal and Institutional, Coordinating PI: MSD. M.J. Krzakowski: Financial Interests, Personal, Other, travel grant: MSD; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Other, Travel grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1543P - Clinical study of camrelizumab combined with docetaxel and carboplatin in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
Presenter: Rui Wang
Session: Poster session 21
1544P - Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
Presenter: Xin fang Hou
Session: Poster session 21
1545P - Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus
Presenter: Yuexiao Qi
Session: Poster session 21
1546P - Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer
Presenter: Hidekazu Hirano
Session: Poster session 21
1547P - SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
Presenter: Chiaki Inagaki
Session: Poster session 21
1549P - A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
Presenter: Hiroyuki Takeda
Session: Poster session 21
1551P - Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer
Presenter: Choong-kun Lee
Session: Poster session 21
1552P - Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
Presenter: Tania Fleitas
Session: Poster session 21
1553P - Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study
Presenter: Benthe Doeve
Session: Poster session 21